Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Synergistic efficacy and preliminary molecular mechanisms of venetoclax combined with microtransplantation in the treatment of elderly patients with Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYuxian HuangJWJiayue WeiZLZiwei Liu

Discussion

Loading...

Member takes

Overview

Survival analysis shows venetoclax improves outcomes in elderly AML patients, suggesting targeted therapy may enhance immunotherapy effectiveness.

Key Points

  • To evaluate the efficacy of venetoclax combined with microtransplantation in elderly patients with acute myeloid leukemia.
  • Enrolled 18 elderly AML patients with intermediate and high-risk after induction therapy.
  • Evaluated safety and efficacy of venetoclax with microtransplantation as consolidation therapy.
  • Employed flow cytometry to assess cytotoxicity of NK and CD8⁺T cells against AML cells.
  • 2-year overall survival rate of 77.8% with median OS of 53.0 months.
  • No acute or chronic graft-versus-host disease recorded.
  • Venetoclax enhanced the cytotoxic activity of NK and CD8⁺T cells by activating NKG2D/NKG2DL signaling.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2eehttps://doi.org/10.1182/blood-2025-7794
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical Effects of Venetoclax in the Treatment of Acute Myeloid Leukemia in the Elderly2024
  2. 2Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies2026
  3. 3Venetoclax‐based non‐intensive induction followed by allogenic stem‐cell transplantation in elderly acute myeloid leukemia patients with adverse cytogenetics2024
  4. 4Low‑dose venetoclax combined with azacitidine in older and frail patients with newly diagnosed acute myeloid leukaemia2024 · 3 citations
  5. 5Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation2025 · 4 citations